98%
921
2 minutes
20
Background: The association between proton pump inhibitors (PPIs) and stroke remains controversial, while H receptor antagonists (HRAs) have been less studied in relation to stroke. This study aimed to explore the relationship between PPIs, HRAs, and overall acid-suppressant medications with stroke using data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018.
Methods: Data on acid-suppressant use were obtained from the NHANES prescription medication survey for the past month, classifying individuals using PPIs or H2RAs as acid-suppressant users. Stroke data were derived from the disease questionnaire. Propensity score matching (PSM) was applied to reduce intergroup differences, followed by weighted multivariable logistic regression and subgroup analyses to examine the association between acid-suppressant use (including the use of PPIs and H2RAs) and stroke.
Results: A total of 54,918 participants were included before matching, among whom 5,776 (10.5%) were acid-suppressant users. Stroke was reported in 551 (9.5%) acid-suppressant users and in 1,643 (3.3%) of the 49,142 non-users. After 1:3 propensity score matching, 14,390 participants were retained, including 3,740 acid-suppressant users and 10,650 non-users. Among them, 316 users (8.4%) and 614 non-users (5.8%) reported having had a stroke. Weighted logistic regression analysis indicated a significant association between acid-suppressant use and stroke. The association remained statistically significant both before matching (OR: 1.37, 95% CI: 1.15-1.63, P < 0.001) and after matching (OR: 1.33, 95% CI: 1.10-1.60, P = 0.003). In addition, the association between H2RA use and stroke remained significant before and after matching, whereas the association between PPI use and stroke appeared less stable, showing borderline significance.
Conclusion: Our findings suggest a significant association between the use of acid-suppressive medications and stroke; however, due to the limitations of cross-sectional study design and self-reported data, this result requires further verification in future research.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12376369 | PMC |
http://dx.doi.org/10.1186/s12883-025-04334-x | DOI Listing |
BMC Neurol
August 2025
The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China.
Background: The association between proton pump inhibitors (PPIs) and stroke remains controversial, while H receptor antagonists (HRAs) have been less studied in relation to stroke. This study aimed to explore the relationship between PPIs, HRAs, and overall acid-suppressant medications with stroke using data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018.
Methods: Data on acid-suppressant use were obtained from the NHANES prescription medication survey for the past month, classifying individuals using PPIs or H2RAs as acid-suppressant users.
Therap Adv Gastroenterol
July 2025
School of Pharmacy and Institute of New Drug Development, Jeonbuk National University, Geonji-ro 20, Jeonju 54907, Republic of Korea.
Background: Recent changes in the acid-related disease market, particularly the emergence of potassium-competitive acid blockers (P-CABs), require an updated analysis of trends in gastric acid suppressant utilization.
Objectives: As the use of P-CAB expands globally, a cross-sectional study is needed to assess its association with potential adverse events from a pharmacovigilance perspective.
Design: Cross-sectional study.
Chin Med J (Engl)
March 2025
Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China.
Background: Several randomized controlled studies have suggested that the prophylactic use of proton pump inhibitors (PPIs) in intensive care unit (ICU) patients could not reduce the incidence of gastrointestinal bleeding (GIB) and may increase adverse events such as intestinal infection and pneumonia. Gut microbiota may play a critical role in the process. PPIs have been widely prescribed for GIB prophylaxis in patients with acute coronary syndrome (ACS).
View Article and Find Full Text PDFPharmazie
December 2023
Laboratory of Drug Informatics, Gifu Pharmaceutical University; Corresponding author: Mitsuhiro Nakamura, Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan ac. jp.
Magnesium oxide is widely used for treating opioid-induced constipation, a serious analgesic-associated problem. Opioid analgesic users are often prescribed non-steroidal anti-inflammatory drugs, which are sometimes combined with acid suppressants to prevent gastrointestinal adverse events. Magnesium preparations combined with acid suppressants may diminish magnesium preparations' laxative effect.
View Article and Find Full Text PDFKorean J Intern Med
March 2024
Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea.
Background/aims: Mucoprotective agents, such as eupatilin, are often prescribed to prevent gastrointestinal (GI) bleeding in addition to an acid suppressant despite the absence of a large-scale study. We evaluated the additional effect of eupatilin on the prevention of GI bleeding in both the upper and lower GI tract in concomitant aspirin and acid suppressant users using the nationwide database of national claims data from the Korean National Health Insurance Service (NHIS).
Methods: An aspirin cohort was constructed using the NHIS claims data from 2013 to 2020.